Gilead Sciences (NASDAQ:GILD – Get Free Report) is expected to post its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $2.18 per share and revenue of $7.79 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year. On average, analysts expect Gilead Sciences to post ($0.47) EPS for the current fiscal year and $9.91 EPS for the next fiscal year.
Gilead Sciences Stock Down 1.9%
NASDAQ:GILD opened at $153.57 on Thursday. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $160.51. The company has a market cap of $190.42 billion, a price-to-earnings ratio of -57.52 and a beta of 0.31. The stock has a fifty day simple moving average of $148.36 and a 200-day simple moving average of $137.60. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were issued a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently -122.85%.
Analysts Set New Price Targets
Several research analysts recently commented on GILD shares. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Barclays decreased their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Zacks Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Finally, Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $159.63.
Read Our Latest Research Report on GILD
Insider Activity
In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the insider owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $147.90, for a total value of $2,218,500.00. Following the transaction, the chief executive officer owned 566,683 shares in the company, valued at approximately $83,812,415.70. This trade represents a 2.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 111,000 shares of company stock worth $15,877,860. Company insiders own 0.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Read More
- Five stocks we like better than Gilead Sciences
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
